10-Q: Amarin Corp. Q2 2026 Earnings: Revenue Decline Amidst Strategic Shifts

Amarin Corporation plc reported a significant decrease in total revenue for Q2 2026, primarily driven by a substantial drop in licensing and royalty income, alongside a moderate decline in product revenue.

Summary

• Amarin Corporation plc reported total revenue of $42.2 million for the three months ended June 30, 2026, a decrease of 42% compared to $72.7 million in the same period of 2025.
• Product revenue, net, decreased by 16% to $39.1 million for Q2 2026 from $46.6 million in Q2 2025, attributed to lower net selling prices in the U.S. and changes in business structure in Europe.
• Licensing and royalty revenue saw a significant decrease of 88% to $3.1 million in Q2 2026 from $26.1 million in Q2 2025, largely due to the prior year recognition of a $25.0 million upfront payment from the Recordati agreement.
• Cost of goods sold increased by 22% to $27.2 million in Q2 2026 from $22.4 million in Q2 2025, leading to a decrease in gross margin.
• Selling, general, and administrative expenses decreased by 43% to $22.2 million in Q2 2026 from $38.7 million in Q2 2025, primarily due to cost reductions from the Global Restructuring Plan.
• Net loss for Q2 2026 was $7.7 million, an improvement from a net loss of $14.1 million in Q2 2025.
• The company ended the quarter with $143.6 million in cash and cash equivalents and $171.1 million in short-term investments, totaling $314.6 million in liquidity, with no debt outstanding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, reduced gross margins, and ongoing challenges from generic competition, despite an improvement in net loss and a strong liquidity position.

Positives

• Net loss improved to $7.7 million in Q2 2026 from $14.1 million in Q2 2025.
• U.S. branded VASCEPA prescriptions increased by 17% in Q2 2026 compared to Q2 2025.
• Overall IPE market in the U.S. increased by 3% in Q2 2026 compared to Q2 2025.
• Amarin's share of the U.S. IPE market increased to approximately 48% in Q2 2026 from 43% in Q2 2025.
• The company maintains a strong liquidity position with $314.6 million in cash and short-term investments and no outstanding debt as of June 30, 2026.

Negatives

• Total revenue decreased by 42% to $42.2 million in Q2 2026 compared to $72.7 million in Q2 2025.
• Product revenue, net, decreased by 16% to $39.1 million in Q2 2026 compared to $46.6 million in Q2 2025.
• Licensing and royalty revenue decreased by 88% to $3.1 million in Q2 2026 compared to $26.1 million in Q2 2025.
• Gross margin decreased significantly to 30% in Q2 2026 from 52% in Q2 2025.
• Cost of goods sold increased by 22% to $27.2 million in Q2 2026 from $22.4 million in Q2 2025.

Risks

• Continued generic competition in the U.S. market for VASCEPA.
• Potential for future changes in net selling prices due to customer mix.
• Reliance on third-party commercial partners for international market access and sales.
• Uncertainty in the timing and amount of future licensing and royalty revenues.
• Potential for supply chain disruptions or failure to renew supply agreements on favorable terms.
• Antitrust litigation and other legal proceedings could result in significant costs and liabilities.
• The company's ability to successfully commercialize VASCEPA and VAZKEPA globally.
• Risks associated with regulatory filings, clinical programs, and the safety and efficacy of product candidates.

Future Outlook

The company plans to continue managing its market leadership in the U.S. and drive expanded access and patient uptake of VASCEPA through ongoing support of its commercialization partners and their initiatives in non-U.S. geographies. The amount of supply to purchase in future periods will depend on revenue growth and minimum purchase commitments. The company continues to negotiate with contract suppliers to align supply arrangements with current and future global market demand. The company has not commenced share repurchases but will continue to monitor business and market conditions.

Management Comments

• Despite the generic competition in the U.S., we remain confident that the global patient need for VASCEPA is high.
• For the remainder of 2026, we will continue to (i) competitively manage our market leadership in the U.S., and (ii) drive expanded access and increased patient uptake of VASCEPA through ongoing support of our commercialization partners and their pricing, reimbursement and licensure initiatives in non-U.S. geographies around the world.

Industry Context

StockSavvy.ai notes that Amarin's Q2 2026 results reflect the ongoing challenges of navigating a competitive pharmaceutical market, particularly with the introduction of generic alternatives. The significant drop in licensing revenue highlights the impact of strategic partnerships and upfront payments on short-term financial performance, while the slight increase in U.S. market share for VASCEPA indicates resilience in its core market.

Comparison to Industry Standards

• The decrease in gross margin from 52% to 30% for product sales is a significant deviation from typical pharmaceutical industry benchmarks, which often maintain higher margins due to patent protection and market exclusivity. This decline is attributed to a change in customer mix and potentially increased pricing pressures.
• The company's R&D spending as a percentage of revenue remains substantial, consistent with the pharmaceutical industry's investment in innovation and pipeline development, though it has decreased slightly year-over-year.
• The net loss, while improved, still indicates that the company is not yet profitable, a common challenge for many biopharmaceutical companies in their growth or commercialization phases, especially those facing generic competition.

Legal Proceedings

• Patent infringement lawsuit against Hikma, with the Supreme Court reversing a prior decision and remanding the case.
• Former CEO Karim Mikhail filed a complaint for alleged constructive termination, with ongoing legal proceedings.
• Antitrust lawsuits filed by Dr. Reddys, Hikma, Teva, and Apotex alleging anticompetitive practices.
• Six putative antitrust class action lawsuits alleging monopolization and conspiracy to restrain trade in the IPE drug and API markets, with a confidential settlement agreement reached with Purchaser Plaintiffs.
• The company believes it has valid defenses and will vigorously defend against remaining claims in ongoing litigation.

Stakeholder Impact

• Shareholders may be concerned by the significant revenue decline and reduced gross margins, although the improved net loss and strong liquidity may offer some reassurance.
• Customers (wholesalers, pharmacies) may experience shifts in pricing and supply dynamics due to changes in Amarin's sales strategy and market share.
• Suppliers are subject to ongoing negotiations for supply agreements, with potential impacts on future demand and pricing.
• Employees may be affected by cost-saving measures related to the Global Restructuring Plan, as indicated by reduced SG&A expenses.

Next Steps

• Continue to competitively manage market leadership in the U.S.
• Drive expanded access and increased patient uptake of VASCEPA through ongoing support of commercialization partners.
• Pursue pricing, reimbursement, and licensure initiatives in non-U.S. geographies.
• Monitor business and market conditions for potential share repurchases.
• Continue to negotiate with contract suppliers to align supply arrangements with current and future global market demand.

Key Dates

Recommendation

While the company shows resilience in its U.S. market share and maintains a strong liquidity position, the significant revenue decline, reduced gross margins, and ongoing legal challenges present considerable headwinds. The improvement in net loss is positive, but the overall financial performance indicates a need for caution. A 'hold' recommendation reflects the balance between these factors, suggesting investors await clearer signs of sustained revenue growth and margin improvement before considering a more aggressive stance.

Keywords

VASCEPA, icosapent ethyl, cardiovascular health, triglycerides, REDUCE-IT, pharmaceutical, drug commercialization, European Union